By Carol Young, Nerac Analyst,
Originally Published: January 20, 2016
Risk Assessment plays an important role in getting products approved and placed on market, and while post market surveillance is not a new requirement, it is now clear that the notified bodies have placed an increased focus in this area and expect it to be an essential component of the overall clinical evaluation of marketed devices. Make sure you are covered here.
Want to read the rest of the article? Fill out the form to download: Risk Assessment and the Value of a Comprehensive Post-Market Surveillance Program
Related Posts
- 76By Ron Sills, Nerac Analyst Originally Published: September 29th, 2014 The European Union’s Council Directive 93/42/EEC concerning medical devices contains the essential requirements to be met by medical device manufacturers in order to market their products in the 28 member countries. A technical file for Class IIa and IIb devices, or a design dossier for…
- 58By Robert Zott, Director of Advisory Services Originally Published: July 18, 2018 The publication of the new Medical Device Regulation (MDR) 2017/745 in the European Journal, with its entry into force on May 25, 2017, marks the end of an eight-year period of controversy, and the beginning of a three-year transition to the most sweeping…
- 56By Robert Zott, Director of Advisory Services Development Originally published November 13, 2018 There is now 1 year, 6 months and 20 days until the application date upon which the new European Medical Device Regulation (MDR) goes into effect. For those charged with the task of upgrading systems for MDR compliance, that’s 567 days or…